TriangleNCT03635567 · OUTCOME
Number of Participants Who Experienced an Immune-related AE (irAE)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Number of Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to approximately 66 months
What was measured
AEs associated with pembrolizumab exposure may be a result of an immune response. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. For this study irAEs included, but were not limited to: -Pneumonitis; * Diarrhea/Colitis; * Aspartate transaminase (AST)/Alanine transaminase (ALT) elevation or Increased bilirubin; * Type 1 diabetes mellitus or Hyperglycemia; * Hypophysitis; * Hyperthyroidism; * Hypothyroidism; * Nephritis and Renal dysfunction; and * Myocarditis. The number of participants who experienced an irAE is presented.
Analysis population: All randomized participants who received at least one dose of study treatment.
Groups in this outcome
Pembrolizumab+Chemotherapy
On Day 1 of each 21-day cycle, participants received an intravenous (IV) infusion of pembrolizumab 200 mg for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\^2 PLUS cisplatin 50 mg/m\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\^2 PLUS carboplatin Area Under the Curve (AUC) 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
Placebo+Chemotherapy
On Day 1 of each 21-day cycle, participants received an IV infusion of placebo (Normal Saline or Dextrose solution) for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\^2 PLUS cisplatin 50 mg/m\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\^2 PLUS carboplatin AUC 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity.
| Group | Source count |
|---|---|
| Pembrolizumab+Chemotherapy | 307 |
| Placebo+Chemotherapy | 309 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pembrolizumab+Chemotherapy | 134 | Not reported | Not reported | Not reported | Not reported |
| Placebo+Chemotherapy | 92 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 134
- group Id
- OG001
- value
- 92
- denoms
- counts
- group Id
- OG000
- value
- 307
- group Id
- OG001
- value
- 309
- units
- Participants
- description
- AEs associated with pembrolizumab exposure may be a result of an immune response. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. For this study irAEs included, but were not limited to: -Pneumonitis; * Diarrhea/Colitis; * Aspartate transaminase (AST)/Alanine transaminase (ALT) elevation or Increased bilirubin; * Type 1 diabetes mellitus or Hyperglycemia; * Hypophysitis; * Hyperthyroidism; * Hypothyroidism; * Nephritis and Renal dysfunction; and * Myocarditis. The number of participants who experienced an irAE is presented.
- groups
- description
- On Day 1 of each 21-day cycle, participants received an intravenous (IV) infusion of pembrolizumab 200 mg for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\^2 PLUS cisplatin 50 mg/m\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\^2 PLUS carboplatin Area Under the Curve (AUC) 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
- id
- OG000
- title
- Pembrolizumab+Chemotherapy
- description
- On Day 1 of each 21-day cycle, participants received an IV infusion of placebo (Normal Saline or Dextrose solution) for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\^2 PLUS cisplatin 50 mg/m\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\^2 PLUS carboplatin AUC 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity.
- id
- OG001
- title
- Placebo+Chemotherapy
- param Type
- NUMBER
- population Description
- All randomized participants who received at least one dose of study treatment.
- reporting Status
- POSTED
- time Frame
- Up to approximately 66 months
- title
- Number of Participants Who Experienced an Immune-related AE (irAE)
- type
- SECONDARY
- unit Of Measure
- Number of Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice